Answers are grounded in this paper and cite their sources.
Subgroup analysis reveals improved efficacy and safety outcomes with selinexor dose reduction in lenalidomide-refractory multiple myeloma patients, suggesting a beneficial treatment approach.
A subgroup analysis of efficacy, safety and QOL in patients who received selinexor in combination with bortezomib and dexamethasone (SVd) with and without selinexor dose reduction and who had lenalidomide-refractory disease in the phase 3 BOSTON trial showed improvements in efficacy, quality of life (QOL) and safety outcomes with selinexor dose reduction in this difficult-to-treat population. These findings demonstrate the benefit of selinexor dose reductions in optimizing the treatment of patients with lenalidomide-refractory multiple myeloma (MM) receiving SVd.
No takes yet. Share an insight, caveat, or question.
Delimpasi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: